|

68Ga-DOTATOC Clinical Trials

2 actively recruiting trials

Pipeline

Phase 3: 2

Top Sponsors

  • University Hospital, Grenoble1
  • Jiangsu HengRui Medicine Co., Ltd.1

Indications

  • Cancer2
  • Advanced Gastroenteropancreatic Neuroendocrine Tumor1
  • Breast Cancer, Metastatic1
  • Breast Cancer1

Other2 trials

Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer
Phase 3
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.